Federal Register of Legislation - Australian Government

Primary content

PB 93 of 2022 Arrangements as made
This instrument amends the National Health (Growth Hormone Program) Special Arrangement 2015 (PB 85 of 2015) to add, delete and make changes to the drugs listed in Schedule 1, including the associated forms, manners of administration, brands and section 100 only status.
Administered by: Health and Aged Care
Registered 30 Sep 2022
Tabling HistoryDate
Tabled HR25-Oct-2022
Tabled Senate25-Oct-2022
Date of repeal 09 Feb 2023
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.

 

Commonwealth Coat of Arms of Australia

 

PB 93 of 2022

 

National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2022 (No. 1)

 

National Health Act 1953

 

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the National Health Act 1953.

Date     29 September 2022                                                     

 

 

 

 

 

 

 

 

 

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

 

 


Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Growth Hormone Program) Special Arrangement 2015
(PB 85 of 2015)
                                                                                                                                      2

 

 

 


1        Name

(1)          This instrument is the National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2022 (No. 1).

(2)          This instrument may also be cited as PB 93 of 2022.

2        Commencement

(1)          Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 October 2022, immediately after the commencement of the National Health (Growth Hormone Program) Special Arrangement Amendment (Mecasermin and Somatrogon) Instrument 2022 (PB 92 of 2022)

1 October 2022

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)               Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3        Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

4        Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

 

 

 

 


Schedule 1     Amendments

National Health (Growth Hormone Program) Special Arrangement 2015 (PB 85 of 2015)

[1]        Schedule 1, Part 1, Pharmaceutical benefits for treatment of children

substitute:

Part 1 – Pharmaceutical benefits for treatment of children

Listed Drug

Form

Manner of Administration

Brand

Section 100 only

Mecasermin

Solution for injection 40 mg in 4 mL (10 mg per mL)

Injection

Increlex

D(100)

Somatrogon

Injection 24 mg in 1.2 mL single use pre-filled pen

Injection

Ngenla

D(100)

 

Injection 60 mg in 1.2 mL single use pre-filled pen

Injection

Ngenla

D(100)

Somatropin

Injection 0.4 mg (1.2 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 0.6 mg (1.8 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 0.8 mg (2.4 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 1 mg (3 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 1.2 mg (3.6 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 1.4 mg (4.2 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 1.6 mg (4.8 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 1.8 mg (5.4 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 2 mg (6 i.u.) with diluent in single use syringe (without preservative)

Injection

Genotropin MiniQuick

D(100)

 

Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)

Injection

Humatrope

D(100)

 

Injection 36 i.u. (12 mg) cartridge with 3.15 mL diluent (with preservative)

Injection

Humatrope

D(100)

 

Injection 72 i.u. (24 mg) cartridge with 3.15 mL diluent (with preservative)

Injection

Humatrope

D(100)

 

Powder for injection 5 mg (15 i.u.) with diluent in pre‑filled pen (with preservative)

Injection

Genotropin GoQuick

D(100)

 

Powder for injection 12 mg (36 i.u.) with diluent in pre‑filled pen (with preservative)

Injection

Genotropin GoQuick

D(100)

 

Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Omnitrope Surepal 5

D(100)

 

 

 

Scitropin A

D(100)

 

Solution for injection 5 mg (15 i.u.) in 1.5 mL cartridge (with preservative) in a pre‑filled pen

Injection

Norditropin FlexPro

D(100)

 

Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)

Injection

Saizen

D(100)

 

Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Omnitrope Surepal 10

D(100)

 

 

 

SciTropin A

D(100)

 

Solution for injection 10 mg (30 i.u.) in 1.5 mL cartridge (with preservative) in a pre‑filled pen

Injection

Norditropin FlexPro

D(100)

 

Solution for injection 10 mg (30 i.u.) in 2 mL cartridge (with preservative)

Injection

NutropinAq

D(100)

 

Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Saizen

D(100)

 

Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Omnitrope Surepal 15

D(100)

 

Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative) in a pre‑filled pen

Injection

Norditropin FlexPro

D(100)

 

Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)

Injection

Saizen

D(100)